August 2009
Worldwide Biotech;Aug2009, Vol. 21 Issue 8, p4
Trade Publication
The article announces that the U.S. Centers for Disease Control & Prevention (CDC) Advisory Committee on Immunization Practices updated its Japanese Encephalitis (JE) recommendations and include IXIARO, a JE vaccine from Intercell AG. It reveals why ACIP made significant changes to their recommendations. The U.S. Food & Drug Administration gave marketing approval to IXIARO on March 30, 2009. A brief background of JE, IXIARO and Intercell AG is presented.


Related Articles

  • Recommendations for Use of a Booster Dose of Inactivated Vero Cell Culture-Derived Japanese Encephalitis Vaccine -- Advisory Committee on Immunization Practices, 2011. Hills, Susan L.; Fischer, Marc // MMWR: Morbidity & Mortality Weekly Report;5/27/2011, Vol. 60 Issue 20, p661 

    The article presents recommendations for the use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis (JE) vaccine by the Center for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP). The recommendations included data on the use of a...

  • IXIARO: A New Japanese Encephalitis Vaccine. Deresinski, Stan // Infectious Disease Alert;Aug2009, Vol. 28 Issue 11, p91 

    The article offers information on the IXIARO® vaccine developed against Japanese encephalitis virus (JEV), a flavivirus transmitted by rice field-breeding mosquitoes who have fed on wild birds or domestic pigs. The IXIARO® vaccine was approved by the U.S. Food and Drug Administration (FDA)...

  • ACIP covers Japanese encephalitis, pertussis, and rotavirus vaccines. Foster, Stephan L. // Pharmacy Today;Aug2013, Vol. 19 Issue 8, p23 

    The article reports on the issues addressed by the Advisory Committee on Immunization Practices (ACIP) at its meeting held in Atlanta, Georgia on June 19-20, 2013. The topic of the meeting focuses on the development of vaccines for Japanese encephalitis (JE), pertussis and rotavirus. The...

  • ACIP addresses variety of vaccine topics at meeting. Foster, Stephan L. // Pharmacy Today;May2013, Vol. 19 Issue 5, p30 

    The article focuses on the vaccines which was discussed at the Advisory Committee on Immunization Practice (ACIP) meeting, including 13-valent pneumococcal conjugate vaccine (PCV13), Japanese encephalitis (JE) vaccine, and tetanus-diphtheria-acellular pertussis (Tdap) vaccine. It mentions that...

  • Intercell Gets Stock Boost as FDA Approves Ixiaro. Sheridan, Cormac // BioWorld International;4/1/2009, Vol. 14 Issue 13, p1 

    The article reports that U.S. Food and Drug Administration (FDA) approval of Intercell AG's Japanese Encephalitis Virus (JEV) vaccine Ixiaro resulted to a 10.7% increase in its share price on March 30, 2009. Earlier, a positive opinion from the European Medicines Agency was obtained by the...

  • Intercell Gets Stock Boost as FDA Approves Ixiaro.  // Bioworld Week;4/6/2009, Vol. 17 Issue 14, p4 

    The article reports that the Food & Drug Administration (FDA) approval of the Japanese Encephalitis Virus (JEV) vaccine Ixiaro boosts the shares in Intercell AG in the U.S. The stock closed at 23.20 euro, increased by 10.7 percent. The company and its distribution partner Novartis AG, are...

  • ACIP to reconsider Japanese encephalitis vaccine recommendation.  // Infectious Disease News;Nov2013, Vol. 26 Issue 11, p27 

    The article reports on the plan by the U.S. Advisory Committee on Immunization Practices to evaluate recommendations for the Japanese encephalitis vaccine in 2013.

  • Intercell Files BLA, MAA For Encephalitis Vaccine. Sheridan, Cormac // BioWorld International;1/2/2008, Vol. 13 Issue 1, p1 

    The article reports on the success of Intercell AG to complete the biologics license application filing for its lead product, a cell-culture-based vaccine against Japanese encephalitis virus (JEV), just before Christmas of 2007. According to Gerd Zettlmeissl, CEO of Intercell, the completion is...

  • Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Use of CSL Seasonal Influenza Vaccine (Afluria) in the United States During 2010-11.  // JAMA: Journal of the American Medical Association;12/1/2010, Vol. 304 Issue 21, p2353 

    The article deals with the recommendations of the U.S. Advisory Committee on Immunization Practices (ACIP) on the use of the seasonal influenza vaccine Afluria of CSL in the U.S. for the 2010-2011 period. The warning and precautions section of the Afluria package insert for the 2010-2011...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics